The company's goal is to provide patients with knee osteoarthritis an alternative treatment that eliminates chronic pain, restores mobility, and stops disease progression. Their solution involves the use of bioresorbable embolic particles and a balloon occlusion microcatheter, which are designed to be more effective and less invasive than current treatments. CrannMed is currently in the pre-seed stage of development and is focused on bringing their innovative solution to market.